Drug Approval Processes (e.g., FDA, EMA)
Start with the big picture
Before human studies, sponsors submit an Investigational New Drug application (IND) to the FDA or a Clinical Trial Application (CTA) in the EU. Clinical development proceeds through phases that examine safety, dose-finding, efficacy, and later monitoring. Marketing submissions include an FDA New Drug Application (NDA) or Biologics License Application (BLA), and an EMA Marketing Authorisation Application (MAA), with different EU review routes. The topic also compares review bodies and expedited pathways, and introduces regulatory approaches for generics, biosimilars, pediatric studies, and orphan medicines. Across both regions, quality standards and ethical safeguards support development, while risk-management plans and pharmacovigilance systems continue after authorization. These are broad pathway distinctions; the full lesson organizes the comparison across the development lifecycle.
What you'll learn
- Outline the transition from preclinical data to authorization for human studies.
- Distinguish major FDA and EMA marketing submission routes.
- Describe the purpose of clinical development phases.
- Identify regulatory approaches for generics, biosimilars, and pediatric studies.
- Explain how ethical oversight and post-marketing monitoring support public health.
Continue your study
Work through the complete notes and reinforce the topic with the study tools available in the full lesson.
